

News Release



Contact: Vedad Mešanović
(+381 65 383 2150)
vedad@glialab.com

GliaLab Achieves Milestone Using Artificial Intelligence in Breast Cancer Detection

CHICAGO, LOS ANGELES and Belgrade, February 15, 2017 — GliaLab, a global research lab using artificial intelligence to advance modern medicine, has achieved a 91% accuracy rate on its proprietary Computer Aided Diagnostic (“CAD”) device designed to detect breast cancer using a standard mammogram image.

“Our proprietary algorithm driving the exponential success of the CAD device continues to exceed our expectations” said Abu Qader, Chief Technology Officer for GliaLab. “Achieving a 91% accuracy rate at this early stage of our development process is a leading indicator of the massive impact this disruptive technology will have on early and accurate diagnosis of breast cancer.” The combination of GliaLab’s powerful machine learning software, adaptable design and simple user interface will soon become an indispensable tool for reading mammogram images.

GliaLab developed this technology as a complementary diagnostic, providing radiologist with a highly accurate “second opinion” tool to identify and properly classify cancer in dense breast tissue. “Our goal was to create an affordable solution with a simple and practical user interface that could be easily implemented by professionals and patients at the earliest stages of breast cancer diagnosis” said Qader. Our platform is compatible with different desktop and portable devices, giving everyone the opportunity to have an efficient and highly accurate second opinion whenever and wherever they need it.

GliaLab is a leading technology company utilizing machine learning and computer vision to improve cancer diagnosis, and was featured in Crain’s Chicago Business and Market Watch. The firm has significant experience in developing new technologies and applications using machine learning and computer vision. For more information go to glialab.com or follow us on Twitter @GliaLab.

The information presented in this news release may contain forward-looking statements. These statements, which may be expressed in a variety of ways, including the use of future or present tense language, relate to, among other things, expectations with respect to the release of the technology described herein. These statements are based upon current beliefs and expectations and are subject to significant risks and uncertainties (some of which are beyond Glia Lab’s control). All statements in this press release speak only as of the date of this news release, and Glia Lab undertakes no obligation to update any statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of unanticipated events.